SELB SELECTA BIOSCIENCES

Selecta Biosciences to Participate in Upcoming Investor Conferences

Selecta Biosciences to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTORTM, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate virtually in the following investor conferences in October:

Jefferies Virtual Gene Therapy/Editing Summit

Date: Thursday, October 1, 2020

Fireside chat time: 4:30 p.m. ET

Chardan Virtual 4th Annual Genetic Medicines Conference

Date: Monday, October 5, 2020

Fireside chat time: 2:30 p.m. ET

Live webcasts will be available in the Investors & Media section of the company’s website at .

About Selecta Biosciences, Inc.

Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. The company’s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi. For more information, please visit .

For Investors:

Lee M. Stern

Solebury Trout



For Media:

Meredith Sosulski, Ph.D.

LifeSci Communications, LLC



EN
24/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SELECTA BIOSCIENCES

 PRESS RELEASE

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics Announces New Employment Inducement Grant FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of an inducement award to one new employee. On October 2, 2025, the Company issued to this employee an option to purchase an aggregate of 9,700 shares of the Company’s common stock with an exercise price of $10.34, the closing trading price of the Company’s common stock on the Nasdaq Global Market on ...

 PRESS RELEASE

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

Cartesian Therapeutics to Participate in Upcoming Investor Conferences FREDERICK, Md., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September: A fireside chat at the Cantor Global Healthcare Conference 2025 at 11:30 a.m. ET on Thursday, September 4, 2025A fireside chat at Morgan Stanley’s 23rd Annual Healthcare Conference at 4:05 p.m. ET on Tuesday, Sept...

 PRESS RELEASE

Cartesian Therapeutics Reports Second Quarter 2025 Financial Results a...

Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Initiated Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected in 2H25 Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications expected in 2H25 Approximately $162.1 million cash, cash equivalents and restricted cash as of June 30, 2025, expected to support planned operations into mid-2027, including completion of ongoing Phase 3 AURORA trial FREDERICK, Md....

 PRESS RELEASE

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On August 4, 2025, the Company issued to these employees options to purchase an aggregate of 5,750 shares of the Company’s common stock with an exercise price of $12.48, the closing trading price of the Company’s common stock on the Nasdaq Global Market on t...

 PRESS RELEASE

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On June 2, 2025, the Company issued to these employees options to purchase an aggregate of 26,350 shares of the Company’s common stock with an exercise price of $9.98, the closing trading price of the Company’s common stock on the Nasdaq Global Market on t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch